Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|September 5, 2019
OASIS Pooled Results: Omadacycline Safe and Efficacious in IVDU and non-IVDU
Author(s)Michaela Fleming
Investigators have presented the microbiological, efficacy, and safety results in the pooled intravenous drug use vs non-intravenous drug use patients in 2 phase 3 ABSSSI studies, OASIS-1 and 2.
Advertisement
Infections among patients who have a history of intravenous drug use (IVDU) are becoming more common and can present challenges to clinicians treating this population.
Omadacycline, a modern tetracycline with activity against a broad spectrum of bacteria including gram-positive, gram-negative, and drug-resistant strains, was
In a presentation at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, investigators presented the microbiology, efficacy, and safety results in the pooled IVDU vs non-IVDU patients in 2 phase 3 ABSSSI studies, OASIS-1 and 2.
The OASIS-1 study enrolled 655 patients who were randomized 1:1 to receive 100 mg of omadacycline IV every 12 hours twice followed by 100 mg of omadacycline IV every 24 hours, or to receive 600 mg of linezolid IV every 12 hours. After at least 3 days of therapy, patients could transition to 300 mg of oral omadacycline every 24 hours or 600 mg of oral linezolid every 12 hours.
In the OASIS-2 study, 735 patients were randomized 1:1 to receive either 450 mg of omadacycline orally every 24 hours for 2 doses, and then 300 mg of omadacycline orally every 24 hours or to receive 600 mg of linezolid 600 orally every 12 hours.
Duration of treatment was 7-14 days in both OASIS studies. The investigators evaluated efficacy 48 to 72 hours after the first dose, which is reported as early clinical response based upon the reduction of lesion size by at least 20%. The investigators also assessed efficacy 7 to 14 days following the last dose, which is reported as post therapy evaluations based on the investigators’ assessment of clinical response.
The research team also calculated 2-sided 95% confidence intervals for the difference between early clinical response and post therapy evaluations.
The investigators report that in OASIS-1 and 2, 820 IVDU and 527 non-IVDU patients were enrolled into the modified intent-to-treat population. Furthermore, wound infections were more frequently documented in IDCU patients (66%) and cellulitis/erysipelas was reported more often in non-IVDU patients (56%).
The most frequently isolated pathogens were gram-positive aerobes (82% vs 87%) and Staphylococcus aureus (66% vs 67%) in IVDU vs non-IVDU patients, respectively.
The investigators report that “early clinical response successes for omadacycline vs linezolid in IVDU patients was 87.4% vs 85.2% [D (difference) 2.2, 95% CI: -2.5, 7.0] and in non-IVDU was 84.4% VS 81.9% [D 2.5, 95% CI: -4.0, 8.9]. Post treatment efficacy successes for omadacycline vs linezolid in IVDU patients was 80.7% vs 80.0% [D 0.6, 95% CI: -4.8, 6.1] and in non-IVDU patients was 92.0% vs 85.3% [D 6.7, 95% CI: 1.2, 12.3].”
Overall, higher rates of treatment-emergent adverse events were observed in patients with IVDU patients (omadacycline 56.4%, linezolid 46.0%) vs non-IVDU patients (omadacycline 43.2%, linezolid 43.2%).
Rates of nausea and vomiting were found to be higher in omadacycline-treatment IVDU patients (26.3% and 14.1%) compared with omadacycline-treated non IVDU patients (15.4% and 7.5%)
The authors conclude that “S aureus is common in IVDU and non-IVDU ABSSSI and omadacycline showed similar efficacy and safety in IVDU and non-IVDU ABSSSI patients.”
The study, "
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.